Objective

To collect information which helps to define the best use of Fortovase^® (FTV) based on virus genotype, including:

• how often patients are not eligible to receive FTV due to resistance
• clinical outcome of FTV when used optimally according to genotype
• whether failure is associated with resistance to FTV or to RT inhibitors
• best options for switching drug(s) if a patient develops resistance to FTV
• clinical outcome of switch options after using FTV

Concept

• Any prior therapy is allowed, and there are no restrictions on how FTV is prescribed.
• Data are collected: at entry; at 24 and 48 wks.
• If still on same therapy; in the event of failure; then 12 wks. after switch.
• Roche affiliates nominate physicians and labs according to their expertise and resources.
• Roche affiliates can choose the type of gene sequencing technology.
• Physican signs up to the programme and receives RetroGram™ software.

Roche Pharma affiliates provide

• Replacement genotype and viral load (state of the art, ultrasensitive) assays
• Any investigator fees

Roche HQ provides